{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=300+mg+SC", "query": { "intervention": "300 mg SC" }, "page_size": 10 }, "pagination": { "page": 1, "page_size": 10, "total_count": 214, "total_pages": 22, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=300+mg+SC&page=2&page_size=10", "previous_page_url": null }, "source": "remote", "last_synced_at": "2026-09-10T17:05:19.799Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT06581328", "title": "A Study of Vedolizumab in Adults With Ulcerative Colitis or Crohn's Disease in the Community Setting", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE4" ], "conditions": [ "Ulcerative Colitis", "Crohn's Disease" ], "interventions": [ { "name": "Vedolizumab IV", "type": "DRUG" }, { "name": "Vedolizumab SC", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Takeda", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "80 Years", "sex": "ALL", "summary": "18 Years to 80 Years" }, "enrollment_count": 400, "start_date": "2025-03-27", "completion_date": "2028-06-01", "has_results": false, "last_update_posted_date": "2026-08-14", "last_synced_at": "2026-09-10T17:05:19.799Z", "location_count": 101, "location_summary": "Birmingham, Alabama • Mobile, Alabama • Chandler, Arizona + 89 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Mobile", "state": "Alabama" }, { "city": "Chandler", "state": "Arizona" }, { "city": "Gilbert", "state": "Arizona" }, { "city": "Sun City", "state": "Arizona" } ], "official_url": "https://clinicaltrials.gov/study/NCT06581328" }, { "nct_id": "NCT05925049", "title": "A Study Utilising Data From European Union (EU) National Multiple Sclerosis (MS) Registries to Assess the Incidence of Anti-Natalizumab Antibody Among Participants Who Receive Subcutaneous Administration of Natalizumab for Treatment of Relapsing-remitting Multiple Sclerosis (RRMS)", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "OBSERVATIONAL", "phases": [], "conditions": [ "Multiple Sclerosis" ], "interventions": [ { "name": "Natalizumab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Biogen", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "64 Years", "sex": "ALL", "summary": "18 Years to 64 Years" }, "enrollment_count": 400, "start_date": "2023-06-30", "completion_date": "2026-10-31", "has_results": false, "last_update_posted_date": "2026-05-13", "last_synced_at": "2026-09-10T17:05:19.799Z", "location_count": 1, "location_summary": "Cambridge, Massachusetts", "locations": [ { "city": "Cambridge", "state": "Massachusetts" } ], "official_url": "https://clinicaltrials.gov/study/NCT05925049" }, { "nct_id": "NCT01312961", "title": "Efficacy, Safety, and Tolerability of Dupilumab in Patients With Persistent Moderate to Severe Eosinophilic Asthma", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Asthma" ], "interventions": [ { "name": "Dupilumab", "type": "DRUG" }, { "name": "Placebo (for Dupilumab)", "type": "DRUG" }, { "name": "Fluticasone/Salmeterol combination therapy", "type": "DRUG" }, { "name": "Fluticasone monotherapy", "type": "DRUG" }, { "name": "Albuterol", "type": "DRUG" }, { "name": "Levalbuterol", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Sanofi", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "65 Years", "sex": "ALL", "summary": "18 Years to 65 Years" }, "enrollment_count": 104, "start_date": "2011-03", "completion_date": "2012-10", "has_results": true, "last_update_posted_date": "2017-06-08", "last_synced_at": "2026-09-10T17:05:19.799Z", "location_count": 50, "location_summary": "Anaheim, California • Long Beach, California • Los Angeles, California + 42 more", "locations": [ { "city": "Anaheim", "state": "California" }, { "city": "Long Beach", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Mission Viejo", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT01312961" }, { "nct_id": "NCT02392624", "title": "A Study of the Efficacy and Safety of Omalizumab Through 48 Weeks in Participants With Chronic Idiopathic Urticaria", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE4" ], "conditions": [ "Urticaria" ], "interventions": [ { "name": "Omalizumab", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Genentech, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "12 Years", "maximum_age": "75 Years", "sex": "ALL", "summary": "12 Years to 75 Years" }, "enrollment_count": 206, "start_date": "2015-05-18", "completion_date": "2017-03-09", "has_results": true, "last_update_posted_date": "2018-03-29", "last_synced_at": "2026-09-10T17:05:19.799Z", "location_count": 40, "location_summary": "Granada Hills, California • Long Beach, California • Los Angeles, California + 36 more", "locations": [ { "city": "Granada Hills", "state": "California" }, { "city": "Long Beach", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Mission Viejo", "state": "California" }, { "city": "Orange", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT02392624" }, { "nct_id": "NCT04936035", "title": "A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Hypertension" ], "interventions": [ { "name": "Placebo", "type": "DRUG" }, { "name": "ALN-AGT01", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Alnylam Pharmaceuticals", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "75 Years", "sex": "ALL", "summary": "18 Years to 75 Years" }, "enrollment_count": 394, "start_date": "2021-07-07", "completion_date": "2024-12-05", "has_results": true, "last_update_posted_date": "2025-12-23", "last_synced_at": "2026-09-10T17:05:19.799Z", "location_count": 54, "location_summary": "Birmingham, Alabama • Tempe, Arizona • Beverly Hills, California + 44 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Tempe", "state": "Arizona" }, { "city": "Tempe", "state": "Arizona" }, { "city": "Beverly Hills", "state": "California" }, { "city": "La Mesa", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT04936035" }, { "nct_id": "NCT02320721", "title": "Comparison of the Safety and Efficacy of HOE901-U300 With Lantus in Older Patients With Type2 Diabetes Insufficiently Controlled on Their Current Antidiabetic Medications", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Type 2 Diabetes Mellitus" ], "interventions": [ { "name": "Insulin Glargine (HOE901 - U300)", "type": "DRUG" }, { "name": "Insulin Glargine (HOE901 - U100)", "type": "DRUG" }, { "name": "Background therapy", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Sanofi", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "65 Years", "maximum_age": null, "sex": "ALL", "summary": "65 Years and older" }, "enrollment_count": 1014, "start_date": "2015-01", "completion_date": "2016-05", "has_results": true, "last_update_posted_date": "2020-04-21", "last_synced_at": "2026-09-10T17:05:19.799Z", "location_count": 64, "location_summary": "Saraland, Alabama • Fresno, California • Greenbrae, California + 57 more", "locations": [ { "city": "Saraland", "state": "Alabama" }, { "city": "Fresno", "state": "California" }, { "city": "Fresno", "state": "California" }, { "city": "Greenbrae", "state": "California" }, { "city": "Huntington Park", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT02320721" }, { "nct_id": "NCT04180488", "title": "Dupilumab for the Treatment of Chronic Spontaneous Urticaria in Patients Who Remain Symptomatic Despite the Use of H1 Antihistamine and Who Are naïve to, Intolerant of, or Incomplete Responders to Omalizumab (LIBERTY-CSU CUPID)", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Chronic Spontaneous Urticaria" ], "interventions": [ { "name": "Dupilumab SAR231893", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" }, { "name": "non sedating H1-antihistamine", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Sanofi", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "6 Years", "maximum_age": "80 Years", "sex": "ALL", "summary": "6 Years to 80 Years" }, "enrollment_count": 397, "start_date": "2019-12-11", "completion_date": "2024-10-25", "has_results": true, "last_update_posted_date": "2025-08-20", "last_synced_at": "2026-09-10T17:05:19.799Z", "location_count": 16, "location_summary": "Los Angeles, California • Sarasota, Florida • Sweetwater, Florida + 13 more", "locations": [ { "city": "Los Angeles", "state": "California" }, { "city": "Sarasota", "state": "Florida" }, { "city": "Sweetwater", "state": "Florida" }, { "city": "Tampa", "state": "Florida" }, { "city": "Savannah", "state": "Georgia" } ], "official_url": "https://clinicaltrials.gov/study/NCT04180488" }, { "nct_id": "NCT05152563", "title": "A Study to Assess Subcutaneous AK002 in Eosinophilic Gastritis and/or Eosinophilic Duodenitis", "overall_status": "WITHDRAWN", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Eosinophilic Gastritis", "Eosinophilic Duodenitis" ], "interventions": [ { "name": "AK002", "type": "DRUG" }, { "name": "Placebo", "type": "OTHER" } ], "intervention_types": [ "DRUG", "OTHER" ], "sponsor": "Allakos Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "80 Years", "sex": "ALL", "summary": "18 Years to 80 Years" }, "enrollment_count": 0, "start_date": "2021-12", "completion_date": "2022-01-20", "has_results": false, "last_update_posted_date": "2023-03-03", "last_synced_at": "2026-09-10T17:05:19.799Z", "location_count": 76, "location_summary": "Birmingham, Alabama • Gilbert, Arizona • Phoenix, Arizona + 70 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Gilbert", "state": "Arizona" }, { "city": "Phoenix", "state": "Arizona" }, { "city": "Scottsdale", "state": "Arizona" }, { "city": "Chula Vista", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT05152563" }, { "nct_id": "NCT04219540", "title": "Long-acting Buprenorphine vs. Naltrexone Opioid Treatments in CJS-involved Adults", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE4" ], "conditions": [ "Opioid-use Disorder" ], "interventions": [ { "name": "XR-B (SUBLOCADETM)", "type": "DRUG" }, { "name": "XR-NTX", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "NYU Langone Health", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 675, "start_date": "2021-01-07", "completion_date": "2025-02-28", "has_results": false, "last_update_posted_date": "2025-05-14", "last_synced_at": "2026-09-10T17:05:19.799Z", "location_count": 6, "location_summary": "New Haven, Connecticut • Baltimore, Maryland • Hanover, New Hampshire + 3 more", "locations": [ { "city": "New Haven", "state": "Connecticut" }, { "city": "Baltimore", "state": "Maryland" }, { "city": "Hanover", "state": "New Hampshire" }, { "city": "New Brunswick", "state": "New Jersey" }, { "city": "New York", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT04219540" }, { "nct_id": "NCT03510884", "title": "An Efficacy and Safety Study of Alirocumab in Children and Adolescents With Heterozygous Familial Hypercholesterolemia", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Hypercholesterolaemia" ], "interventions": [ { "name": "Alirocumab SAR236553 (REGN727)", "type": "DRUG" }, { "name": "Rosuvastatin", "type": "DRUG" }, { "name": "Atorvastatin", "type": "DRUG" }, { "name": "Simvastatin", "type": "DRUG" }, { "name": "Pravastatin", "type": "DRUG" }, { "name": "Lovastatin", "type": "DRUG" }, { "name": "Fluvastatin", "type": "DRUG" }, { "name": "Ezetimibe", "type": "DRUG" }, { "name": "Cholestyramine", "type": "DRUG" }, { "name": "Nicotinic acid", "type": "DRUG" }, { "name": "Fenofibrate", "type": "DRUG" }, { "name": "Omega-3 fatty acids", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Sanofi", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "8 Years", "maximum_age": "17 Years", "sex": "ALL", "summary": "8 Years to 17 Years" }, "enrollment_count": 153, "start_date": "2018-05-31", "completion_date": "2022-08-05", "has_results": true, "last_update_posted_date": "2023-05-06", "last_synced_at": "2026-09-10T17:05:19.799Z", "location_count": 5, "location_summary": "Boca Raton, Florida • St Louis, Missouri • Charlotte, North Carolina + 2 more", "locations": [ { "city": "Boca Raton", "state": "Florida" }, { "city": "St Louis", "state": "Missouri" }, { "city": "Charlotte", "state": "North Carolina" }, { "city": "Cincinnati", "state": "Ohio" }, { "city": "Nashville", "state": "Tennessee" } ], "official_url": "https://clinicaltrials.gov/study/NCT03510884" } ] }